Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer
Colorectal Cancer, Neoplasm Metastasis
About this trial
This is an interventional treatment trial for Colorectal Cancer focused on measuring colorectal, metastatic, elderly, metastatic colorectal cancer
Eligibility Criteria
Inclusion Criteria: Age 65 years and above; Histologically or cytologically documented adenocarcinoma of the colon or rectum; Metastatic disease; Measurable disease or assessable but nonmeasurable disease allowed; ECOG 0-1 No prior oxaliplatin or bevacizumab. No prior chemotherapy for metastatic disease. Prior adjuvant chemotherapy allowed; No prior fluoropyrimidine therapy (unless give in an adjuvant setting and completed at least 4 months earlier); No bleeding diathesis or coagulopathy Adequate renal and hepatic functions as per protocol; Signed informed consent Exclusion Criteria: Clinically significant cardiovascular or peripheral vascular disease; Concurrent chronic aspirin, nonsteroidal anti-inflammatory drugs, warfarin, or therapeutic heparin; Serious non-healing wound, ulcer, or bone fracture;